147 related articles for article (PubMed ID: 27221150)
1. Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells.
Thulasiraman P; Johnson AB
Int J Oncol; 2016 Aug; 49(2):479-86. PubMed ID: 27221150
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
Hou W; Chen L; Yang G; Zhou H; Jiang Q; Zhong Z; Hu J; Chen X; Wang X; Yuan Y; Tang M; Wen J; Wei Y
Phytother Res; 2008 Aug; 22(8):1125-32. PubMed ID: 18570244
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
4. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1.
Gao M; Miao L; Liu M; Li C; Yu C; Yan H; Yin Y; Wang Y; Qi X; Ren J
Oncotarget; 2016 Sep; 7(37):59714-59726. PubMed ID: 27487127
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.
Xu D; Lu Q; Hu X
Cancer Lett; 2006 Nov; 243(2):274-80. PubMed ID: 16406853
[TBL] [Abstract][Full Text] [Related]
6. Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway.
Yi X; Lou L; Wang J; Xiong J; Zhou S
Cancer Chemother Pharmacol; 2021 May; 87(5):647-656. PubMed ID: 33544209
[TBL] [Abstract][Full Text] [Related]
7. Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase-2.
Singh T; Katiyar SK
Int J Oncol; 2011 Mar; 38(3):769-76. PubMed ID: 21225228
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitizing effect of honokiol in oral carcinoma stem cells via regulation of IL-6/Stat3 signaling.
Chang MT; Lee SP; Fang CY; Hsieh PL; Liao YW; Lu MY; Tsai LL; Yu CC; Liu CM
Environ Toxicol; 2018 Nov; 33(11):1105-1112. PubMed ID: 30076764
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer.
Faneyte IF; Kristel PM; van de Vijver MJ
Anticancer Res; 2004; 24(5A):2931-9. PubMed ID: 15517899
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
11. Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer.
Avtanski DB; Nagalingam A; Bonner MY; Arbiser JL; Saxena NK; Sharma D
Oncotarget; 2015 Oct; 6(30):29947-62. PubMed ID: 26359358
[TBL] [Abstract][Full Text] [Related]
12. Modulation of P-glycoprotein expression by honokiol, magnolol and 4-O-methylhonokiol, the bioactive components of Magnolia officinalis.
Han HK; Van Anh LT
Anticancer Res; 2012 Oct; 32(10):4445-52. PubMed ID: 23060571
[TBL] [Abstract][Full Text] [Related]
13. Honokiol synergizes chemotherapy drugs in multidrug resistant breast cancer cells via enhanced apoptosis and additional programmed necrotic death.
Tian W; Deng Y; Li L; He H; Sun J; Xu D
Int J Oncol; 2013 Feb; 42(2):721-32. PubMed ID: 23242346
[TBL] [Abstract][Full Text] [Related]
14. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
15. The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters.
Rigalli JP; Tocchetti GN; Arana MR; Villanueva SS; Catania VA; Theile D; Ruiz ML; Weiss J
Cancer Lett; 2016 Jun; 376(1):165-72. PubMed ID: 27033456
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells.
Park EJ; Min HY; Chung HJ; Hong JY; Kang YJ; Hung TM; Youn UJ; Kim YS; Bae K; Kang SS; Lee SK
Cancer Lett; 2009 May; 277(2):133-40. PubMed ID: 19135778
[TBL] [Abstract][Full Text] [Related]
17. MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells.
Gana CC; Hanssen KM; Yu DMT; Flemming CL; Wheatley MS; Conseil G; Cole SPC; Norris MD; Haber M; Fletcher JI
Biochem Pharmacol; 2019 Oct; 168():237-248. PubMed ID: 31302132
[TBL] [Abstract][Full Text] [Related]
18. Chemoresistance is associated with overexpression of HAX-1, inhibition of which resensitizes drug-resistant breast cancer cells to chemotherapy.
Yang J; Wu Y; Wang X; Xu L; Zhao X; Yang Y
Tumour Biol; 2017 Mar; 39(3):1010428317692228. PubMed ID: 28347249
[TBL] [Abstract][Full Text] [Related]
19. Honokiol induces paraptosis and apoptosis and exhibits schedule-dependent synergy in combination with imatinib in human leukemia cells.
Wang Y; Yang Z; Zhao X
Toxicol Mech Methods; 2010 Jun; 20(5):234-41. PubMed ID: 20374036
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy.
Kim B; Stephen SL; Hanby AM; Horgan K; Perry SL; Richardson J; Roundhill EA; Valleley EM; Verghese ET; Williams BJ; Thorne JL; Hughes TA
BMC Cancer; 2015 Sep; 15():634. PubMed ID: 26362310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
